MOLECULAR CLONING OF UNIQUE CYTOKINES & PROTOONCOGENES

细胞因子和原癌基因是细胞的关键调节器 功能、生存能力、差异化和沟通。因此， 细胞因子现在被用于许多疾病的治疗。 包括癌症、自身免疫、贫血和肾衰竭。它是 很可能在不久的将来，能够干扰 原癌基因也将在临床上得到应用。长期目标 该项目的主要目的是通过以下途径确定新的细胞因子和原癌基因 一种新型亲和层析技术。使用这一过程，我们 我已经构建了几个基本上是 富含细胞因子和原癌基因的cDNA。35% 从这个文库代码中随机筛选出的cDNA 同等比例的细胞因子或原癌基因是独一无二的 与已知的人类核糖核酸没有同源性。这一阶段的目标 项目为1)。通过以下方式识别文库中的所有新cDNA 部分核苷酸测序和数据库搜索；2)。克隆 组织特异性cDNA中相应的全长cDNA 图书馆。如果成功，我们将申请第二期资金，以 从更多的细胞和组织来源构建新的文库， 描述我们的新型细胞因子和 并开始这些基因的商业化进程 与老牌制药公司合作的重要新分子。 建议的商业应用： 细胞因子和原癌基因与多种疾病有关， 包括癌症。SYMPHONY发明了一种新的克隆方法 这些基因家族的成员基于他们的职位- 转录调控功能。新型细胞因子的克隆 原癌基因将为治疗提供新的靶点 干预。SYMPHONY还开发了一项药物筛选计划 针对这些新的转录后相互作用 已识别的基因将代表潜在的目标。

Cytokines and protooncogenes are critical modulators of cellular function, viability, differentiation and communication. As such, cytokines are now being used in the treatment of many diseases including cancer, autoimmunity, anemia and renal failure. It is likely that in the near future drugs capable of interfering with protooncogenes will also find clinical use. The long term objective of this project is to identify new cytokines and protooncogenes by a novel affinity chromatographic technique. Using this process, we have constructed several cDNA libraries which are substantially enriched for cytokine and protooncogene cDNAs. Thirty-five percent of randomly screened cDNAs from this library code for known cytokines or protooncogenes while an equal percentage are unique without homology to known human mRNAs. The aims of this Phase I project are to 1). identify all novel cDNAs within the library by partial nucleotide sequencing and database search and 2). clone the corresponding full-length cDNAs from tissue specific cDNA libraries. If we are successful, we will apply for Phase 2 funds to construct new libraries from additional cell and tissue sources, characterize the functionality of our novel cytokines and protooncogenes and begin the commercialization process for these important new molecules with established pharmaceutical companies. PROPOSED COMMERCIAL APPLICATION: Cytokines and protooncogenes are implicated in numerous diseases, including cancer. Symphony has developed a novel method of cloning members of these gene families based upon their post- transcriptional regulatory features. The cloning of novel cytokines and protooncogenes will provide new targets for therapeutic intervention. Symphony has also developed a drug screening program targeting post-transcriptional interactions for which these newly identified genes would represent potential targets.